El abordaje de los trastornos de ansiedad debe ser específico

REFERENCES

1. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602.

2. Jacobi F, Hofler M, Strehle J, Mack S, et al.: Mental disorders in the general population: Study on the health of adults in Germany and the additional module mental health (DEGS1-MH). Nervenarzt 2014; 85: 77–87.

3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8–19.

4. Kessler RC, Demler O, Frank RG, Olfson M, et al.: Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005; 352: 2515–23.

5. Jacobi F, Wittchen HU, Holting C, Hofler M, et al.: Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med 2004; 34: 597–611.

6. Bandelow B, Wiltink J, Alpers GW, Benecke C, et al.: Deutsche S3-Leitlinie zur Behandlung von Angststörungen. 2014. www. awmf.org/leitlinien.html (last accessed on 26 May 2014).

7. ÄZQ/AWMF: Deutsches Instrument zur methodischen LeitlinienBewertung (DELBI). 2008: 468–519.

8. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12.

9. SIGN: Scottish Intercollegiate Guidelines Network www.sign.ac. uk. 2012 (last accessed on 26 May 2014).

10. DIMDI: Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme, 10th revised edition. German Modification (ICD-10-GM) 2013.

11. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J: Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002; 63: 24–34.

12. Wittchen HU, Jacobi F: Die Versorgungssituation psychischer Störungen in Deutschland. Eine klinisch-epidemiologische Abschätzung anhand des Bundes-Gesundheitssurveys 1998. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2001; 44: 993–1000.

13. Bandelow B, Boerner RJ, Kasper S, Linden M, Wittchen HU, Möller HJ: The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int 2013; 110: 300–10.

14. Gloster AT, Wittchen HU, Einsle F, Lang T, et al.: Psychological treatment for panic disorder with agoraphobia: A randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. J Consult Clin Psychol 2011; 79: 406–20.

15. Oyebode F, Rastogi A, Berrisford G, Coccia F: Psychotropics in pregnancy: safety and other considerations. Pharmacol Ther 2012; 135: 71–7.

16. Udechuku A, Nguyen T, Hill R, Szego K: Antidepressants in pregnancy: a systematic review. Aust N Z J Psychiatry 2010; 44: 978–96.

17. Tuccori M, Testi A, Antonioli L, Fornai M, et al.: Safety concerns associated with the use of serotonin reuptake inhibitors and oth er serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009; 31: 1426–53.